|
|
 |
|
Viewing report
|
|
|
|
New Approaches to the Treatment of Non-Hodgkin's Lymphoma
Decision Resources, Inc, Dec 2006, Pages: 24
Non-Hodgkin’s lymphoma, consisting of 29 different malignancies of the lymphatic system, is a devastating disease: although treatable, only a small percentage of these cancers are curable, and median survival of aggressive NHLs is poor. While treatment has greatly improved since the introduction of Genentech’s Rituxan in 1997, considerable unmet treatment needs remain, spurring significant development in NHL therapies.
Get the Answers You Need to Shape Your Strategy
Genentech’s Rituxan has generated strong growth in the NHL market since its launch, although Rituxan’s market penetration may have peaked. What factors will drive future growth in the NHL market? Where do opportunities lie in the treatment of NHL? How will emerging agents stack up against Rituxan?
With the launch of new agents, cost will become a driving factor in NHL treatment. Which emerging therapies or drug classes will command the highest prices in the NHL market? How will third-party payers respond to the arrival of potent but potentially expensive NHL therapies?
As many as 20 new therapies are in development for the treatment of NHL. Where will new therapies that arrive on the market fit alongside existing treatment regimens for NHL? What types of NHL will benefit most from new therapies? How will these agents be positioned in the market? What present agents, if any, will face competition?
Scope
Overview of non-Hodgkin’s lymphoma: disease characteristics, risk factors, classification and staging, and diagnosis and prevalence.
Lymphomas covered: follicular lymphoma, B-cell lymphomas, T-cell lymphomas, mantle cell lymphoma.
Current therapies: overview of agents currently in use to treat NHL.
Emerging therapies: a review of leading agents in development for NHL.
Drug classes covered: novel chemotherapy agents, combination therapies, vaccines, monoclonal antibodies, radioimmunotherapies.
Market outlook: our projections for how emerging agents could alter the NHL landscape.
|
|
|
|
